Login to Your Account

MorphoSys Gets $70M for Abd Serotec Unit; Focusing on R&D

By Cormac Sheridan
Staff Writer

Wednesday, December 19, 2012
Six years after building an acquisition-led position in the research and diagnostic antibody space, MorphoSys AG is exiting the field, via a €53 million (US$69.7 million) cash sale of its Abd Serotec unit to Bio-Rad Laboratories Inc.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription